Abstract
Cancer- and treatment-related anemia has received increasing attention, particularly because relationships between anemia and quality of life (QOL) or treatment outcomes are under investigation. This guideline recognizes the multiple etiologies of cancer- and treatment-related anemia, but specifically addresses the treatment of anemia caused by the myelosuppressive effects of chemotherapy and the anemia associated with chronic disease. It provides guidelines for the use of erythropoietic agents in patients with cancer who are receiving chemotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 772-789 |
Number of pages | 18 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 3 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2005 |
Externally published | Yes |
Keywords
- Anemia
- Chemotherapy
- Darbapoetin
- Epoetin
- Erythropoietin
- Ferric gluconate
- Heme iron polypeptide
- Hemoglobin
- Iron dextran
- Iron sucrose
- NCCN Clinical Practice Guidelines in Oncology
- Quality of life
- Serum ferritin
ASJC Scopus subject areas
- Oncology